Literature DB >> 11060499

Mutation L210W of HIV-1 reverse transcriptase in patients receiving combination therapy. Incidence, association with other mutations, and effects on the structure of mutated reverse transcriptase.

N Yahi1, C Tamalet, C Tourrès, N Tivoli, J Fantini.   

Abstract

Mutation L210W of HIV-1 reverse transcriptase (RT) is one of the six main mutations that confer in vivo resistance to zidovudine. Surprisingly, this mutation has received scant appraisal and its contribution to the genotypic resistance to nucleoside analogs is not well understood. The aim of this study was: (1) to study the frequency of mutation L210W in a large collection of HIV-1 sequences (2,049 samples, including 395 DNA and 1,654 RNA sequences) from patients receiving combination therapy, and (2) to analyze its association with the other mutations that confer resistance to zidovudine. A mutation at codon 210 (mainly L210W) was found in 647 (32%) of the 2,049 sequences analyzed. Only 43 (<7%) of these 647 genomes were also mutated at codon 70 (p < 10(-5)). In contrast, 98% of these 647 sequences were also mutated at codon 215 (essentially T215Y/F), and 94% at codon 41 (mainly M41L). These data showing a close association between L210W, T215Y/F, and M41L, and a mutual exclusion between K70R and L210W, were confirmed by analyzing the sequences stored in the HIV-1 sequences available through the Stanford HIV RT and Protease Database. Follow-up studies demonstrated that L210W appeared always after T215Y/F. This observation is consistent with crystallographic studies which suggested that the aromatic side chain of Trp 210 could stabilize the interaction of Phe/Tyr215 with the dNTP-binding pocket. This molecular cross-talk between amino acid chains occurs nearby the conserved Asp113 residue. Since the lateral chain of Arg70 may also interact with Asp113, this is likely to create a sterical hindrance around this residue. Thus, the R-->K reversion of codon 70 may represent a compensatory mechanism allowing a functional rearrangement of the dNTP-binding pocket in the mutated RT. Copyright 2000 National Science Council, ROC and S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11060499     DOI: 10.1007/bf02253366

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  15 in total

Review 1.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

2.  Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistance.

Authors:  Jing Zhang; Tingjun Hou; Wei Wang; Jun S Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-11       Impact factor: 11.205

3.  Drug resistance mutation profile and accumulation kinetics in human immunodeficiency virus-positive individuals infected with subtypes B and F failing highly active antiretroviral therapy are influenced by different viral codon usage patterns.

Authors:  A Waléria-Aleixo; A N Martins; M B Arruda; R M Brindeiro; R M Da-Silva; F F Nobre; D B Greco; A Tanuri
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

4.  Synthesis and antiviral evaluation of 2-amino-6-carbamoylpurine dioxolane nucleoside derivatives and their phosphoramidates prodrugs.

Authors:  Jong Hyun Cho; Lavanya Bondana; Mervi A Detorio; Cathy Montero; Leda C Bassit; Franck Amblard; Steven J Coats; Raymond F Schinazi
Journal:  Bioorg Med Chem       Date:  2014-10-13       Impact factor: 3.641

5.  Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.

Authors:  Zixin Hu; Françoise Giguel; Hiroyu Hatano; Patrick Reid; Jing Lu; Daniel R Kuritzkes
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

6.  Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors.

Authors:  Matthew J Gonzales; Thomas D Wu; Jonathan Taylor; Ilana Belitskaya; Rami Kantor; Dennis Israelski; Sunwen Chou; Andrew R Zolopa; W Jeffrey Fessel; Robert W Shafer
Journal:  AIDS       Date:  2003-04-11       Impact factor: 4.177

7.  Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase.

Authors:  Paul L Boyer; Kalyan Das; Eddy Arnold; Stephen H Hughes
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191

8.  Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility.

Authors:  Maria Carmen Puertas; Maria Jose Buzón; Anna Artese; Stefano Alcaro; Luis Menendez-Arias; Carlo Federico Perno; Bonaventura Clotet; Francesca Ceccherini-Silberstein; Javier Martinez-Picado
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

9.  Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 214.

Authors:  Martin Stürmer; Schlomo Staszewski; Hans-Wilhelm Doerr; Brendan Larder; Stuart Bloor; Kurt Hertogs
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

10.  Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection.

Authors:  Jeffrey A Anderson; Hongyu Jiang; Xiao Ding; Leslie Petch; Terri Journigan; Susan A Fiscus; Richard Haubrich; David Katzenstein; Ronald Swanstrom; Roy M Gulick
Journal:  AIDS Res Hum Retroviruses       Date:  2008-05       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.